Search research articles
Contact Us
Filters
Showing results (91-100 of 395) with videos related to
Page
of 40
Sort By:
Cancer Biology & Therapy
|
February 22, 2014
Pazopanib and HDAC inhibitors interact to kill sarcoma cells
Seyedmehrad Tavallai, Hossein A Hamed, Steven Grant, et al.
Oncotarget
|
November 16, 2017
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy
|
November 4, 2018
Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition
Laurence Booth, Jane L Roberts, Sarah Spiegel, et al.
Molecular Pharmacology
|
August 31, 2006
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells
Xin-Yan Pei, Weiqun Li, Yun Dai, et al.
Cancer Biology & Therapy
|
August 13, 2002
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis
Roy H Decker, Shujie Wang, Yun Dai, et al.
Blood
|
March 25, 2004
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms
Yun Dai, Mohamed Rahmani, Xin-Yan Pei, et al.
Oncotarget
|
December 2, 2016
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
The Journal of Biological Chemistry
|
June 4, 2004
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Yun Dai, Mohamed Rahmani, Seth J Corey, et al.
Gene
|
March 23, 2005
Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms
Sarah M Shore, Sarah A Byers, Paul Dent, et al.
Blood
|
January 16, 2007
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Tri K Nguyen, Mohamed Rahmani, Hisashi Harada, et al.
Page
of 40
Search research articles
Search
Showing results (91-100 of 395) with videos related to
Sort By:
Page
of 40
Cancer Biology & Therapy
|
February 22, 2014
Pazopanib and HDAC inhibitors interact to kill sarcoma cells
Seyedmehrad Tavallai, Hossein A Hamed, Steven Grant, et al.
Oncotarget
|
November 16, 2017
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy
|
November 4, 2018
Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition
Laurence Booth, Jane L Roberts, Sarah Spiegel, et al.
Molecular Pharmacology
|
August 31, 2006
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells
Xin-Yan Pei, Weiqun Li, Yun Dai, et al.
Cancer Biology & Therapy
|
August 13, 2002
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis
Roy H Decker, Shujie Wang, Yun Dai, et al.
Blood
|
March 25, 2004
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms
Yun Dai, Mohamed Rahmani, Xin-Yan Pei, et al.
Oncotarget
|
December 2, 2016
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
The Journal of Biological Chemistry
|
June 4, 2004
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Yun Dai, Mohamed Rahmani, Seth J Corey, et al.
Gene
|
March 23, 2005
Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms
Sarah M Shore, Sarah A Byers, Paul Dent, et al.
Blood
|
January 16, 2007
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Tri K Nguyen, Mohamed Rahmani, Hisashi Harada, et al.
Page
of 40